For how we live.
Tirzepatide and semaglutide showed comparable psychiatric risk profiles against each other over two years. Against earlier GLP-1 drugs, semaglutide came out ahead on all three measures.
The meta-analysis behind ketamine's widening off-label use for suicidal crisis quantifies what 1,166 patients across two decades of trials actually showed — and where the evidence runs out.
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
An Australian cohort of 3,044 children found no protective factor held across all ages and outcomes. School safety mattered at age 6-7; belonging mattered at 12-13.